You-Hong Fan
About
You-Hong Fan is a scholar working on Oncology, Molecular Biology and Immunology.
According to data from OpenAlex, You-Hong Fan has authored 24 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 11 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in You-Hong Fan's work include Lung Cancer Research Studies (11 papers), RNA modifications and cancer (5 papers) and Neuroendocrine Tumor Research Advances (3 papers). You-Hong Fan is often cited by papers focused on Lung Cancer Research Studies (11 papers), RNA modifications and cancer (5 papers) and Neuroendocrine Tumor Research Advances (3 papers). You-Hong Fan collaborates with scholars based in United States. You-Hong Fan's co-authors include Lixia Diao, Lauren A. Byers, John V. Heymach, Jing Wang, Triparna Sen, Lerong Li, Carminia Maria Della Corte, Waun Ki Hong, Ignacio I. Wistuba and B. Leticia Rodriguez and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.
In The Last Decade
You-Hong Fan
23 papers receiving 1.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| You-Hong Fan United States | 13 | 1.0k | 817 | 444 | 190 | 186 | 24 | 1.6k | ||
| You Hong Fan United States | 13 | 841 0.8× | 793 1.0× | 216 0.5× | 83 0.4× | 227 1.2× | 25 | 1.7k | ||
| A. K. El-Naggar United States | 15 | 703 0.7× | 692 0.8× | 279 0.6× | 106 0.6× | 163 0.9× | 24 | 1.5k | ||
| Caj Haglund Finland | 26 | 800 0.8× | 616 0.8× | 90 0.2× | 233 1.2× | 181 1.0× | 52 | 1.6k | ||
| Karwan Moutasim United Kingdom | 17 | 455 0.4× | 440 0.5× | 115 0.3× | 43 0.2× | 193 1.0× | 35 | 1.0k | ||
| Renee M. McGovern United States | 22 | 534 0.5× | 693 0.8× | 111 0.3× | 316 1.7× | 154 0.8× | 50 | 1.5k | ||
| Tibor Görögh Germany | 21 | 412 0.4× | 444 0.5× | 120 0.3× | 177 0.9× | 101 0.5× | 64 | 1.2k | ||
| Simon Laban Germany | 22 | 666 0.7× | 500 0.6× | 351 0.8× | 67 0.4× | 272 1.5× | 127 | 1.3k | ||
| Max D. Wellenstein Netherlands | 9 | 1.3k 1.2× | 691 0.8× | 1.3k 2.8× | 93 0.5× | 307 1.7× | 10 | 2.3k | ||
| Maria Oggionni Italy | 12 | 662 0.7× | 523 0.6× | 83 0.2× | 174 0.9× | 252 1.4× | 15 | 1.6k | ||
| Lerong Li United States | 14 | 827 0.8× | 699 0.9× | 386 0.9× | 232 1.2× | 215 1.2× | 21 | 1.4k |
Countries citing papers authored by You-Hong Fan
Since
Specialization
Citations
This map shows the geographic impact of You-Hong Fan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by You-Hong Fan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites You-Hong Fan more than expected).
Fields of papers citing papers by You-Hong Fan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by You-Hong Fan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by You-Hong Fan. The network helps show where You-Hong Fan may publish in the future.
Co-authorship network of co-authors of You-Hong Fan
This figure shows the co-authorship network connecting the top 25 collaborators of You-Hong Fan. A scholar is included among the top collaborators of You-Hong Fan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with You-Hong Fan. You-Hong Fan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cargill, Kasey R., C. Allison Stewart, Elizabeth M. Park, et al.. (2021). Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. SHILAP Revista de lepidopterología. 9(1). 33–33.
2.
Ramkumar, Kavya, C. Allison Stewart, Kasey R. Cargill, et al.. (2020). AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Molecular Cancer Research. 19(3). 485–497.
3.
Cargill, Kasey R., Carl M. Gay, Robert J. Cardnell, et al.. (2020). Abstract 232: Comprehensive metabolic profiling and vulnerabilities to metabolic inhibitors among small cell lung cancer subtypes. Cancer Research. 80(16_Supplement). 232–232.
4.
Sen, Triparna, B. Leticia Rodriguez, Limo Chen, et al.. (2019). Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery. 9(5). 646–661.
5.
Sen, Triparna, Carminia Maria Della Corte, Snezana Milutinovic, et al.. (2019). Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. Journal of Thoracic Oncology. 14(12). 2152–2163.
6.
Ramkumar, Kavya, Pan Tong, You-Hong Fan, et al.. (2019). Abstract 276: Targeting AXL sensitizes non-small cell lung cancer to ATR inhibitors by enhancing replication stress. Cancer Research. 79(13_Supplement). 276–276.
7.
Corte, Carminia Maria Della, Robert J. Cardnell, Carl M. Gay, et al.. (2019). Abstract B064: The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in small cell lung cancer. Molecular Cancer Therapeutics. 18(12_Supplement). B064–B064.
8.
Gomez, Daniel R., Lauren A. Byers, Monique B. Nilsson, et al.. (2018). Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget. 9(18). 14268–14284.
9.
Morikawa, Naoto, Monique B. Nilsson, Irene Guijarro, et al.. (2018). Abstract 4847: Evaluation of the combination of olaparib and cediranib in small-cell lung cancer cells. Cancer Research. 78(13_Supplement). 4847–4847.
10.
Sen, Triparna, Pan Tong, Lixia Diao, et al.. (2017). Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clinical Cancer Research. 23(20). 6239–6253.
11.
Tsao, Anne S., Heather Lin, Brett W. Carter, et al.. (2017). Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 13(2). 246–257.
12.
Chen, Limo, Lixia Diao, Yongbin Yang, et al.. (2017). Abstract 567: CD38 blockade overcomes the immune resistance to anti-PD-L1 therapy by boosting CD8 T cell response. Cancer Research. 77(13_Supplement). 567–567.
13.
Balaji, Kavitha, Smruthi Vijayaraghavan, Lixia Diao, et al.. (2016). AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research. 15(1). 45–58.
14.
Cardnell, Robert J., Carmen Behrens, Lixia Diao, et al.. (2015). An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clinical Cancer Research. 21(15). 3480–3491.
15.
Cardnell, Robert J., Ying Feng, Lixia Diao, et al.. (2013). Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer. Clinical Cancer Research. 19(22). 6322–6328.
16.
Diao, Lixia, Pan Tong, Jing Wang, et al.. (2013). Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors.. Molecular Cancer Therapeutics. 12(11_Supplement). C117–C117.
17.
Kadara, Humam, Pierre Saintigny, You-Hong Fan, et al.. (2011). Abstract 3674: Gene expression analysis of field of cancerization in early stage NSCLC patients towards development of biomarkers for personalized prevention. Cancer Research. 71(8_Supplement). 3674–3674.
18.
Zhang, Li, J. Jack Lee, Hongli Tang, et al.. (2005). Impact of smoking cessation on global gene expression in bronchial epithelium of chronic smokers. Cancer Research. 65. 207–207.
19.
Mao, Li, V. Papadimitrakopoulou, Dong M. Shin, et al.. (1998). Phenotype and Genotype of Advanced Premalignant Head and Neck Lesions After Chemopreventive Therapy. JNCI Journal of the National Cancer Institute. 90(20). 1545–1551.
20.
Fan, You-Hong, Vassiliki A. Papadimitrakopoulou, Gary L. Clayman, et al.. (1996). DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma.. PubMed. 56(11). 2519–21.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by You Hong Fan Breakdown of academic impact, for papers by A. K. El-Naggar Breakdown of academic impact, for papers by Caj Haglund Breakdown of academic impact, for papers by Karwan Moutasim Breakdown of academic impact, for papers by Renee M. McGovern Breakdown of academic impact, for papers by Tibor Görögh Breakdown of academic impact, for papers by Simon Laban Breakdown of academic impact, for papers by Max D. Wellenstein Breakdown of academic impact, for papers by Maria Oggionni Breakdown of academic impact, for papers by Lerong Li